Carmustine

Generic Name: Carmustine

Brand Names: Bicnu, Gliadel, Carmustine medac (previously Carmustine Obvius)

Drug Type: Small Molecule

Chemical Formula: C_₅H_₉Cl_₂N_₃O_₂

CAS Number: 154-93-8

Unique Ingredient Identifier: U68WG3173Y

Background: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index,...

Indication: For the treatment of brain tumors, multiple myeloma, Hodgkin's disease and Non-Hodgkin's lymphomas.

Associated Conditions: Astrocytoma, Brain Stem Gliomas, Ependymoma, High Grade Glioma: Glioblastoma (GBM), Medulloblastomas, Metastatic Brain Tumors, Mycosis Fungoides (MF), Newly Diagnosed High-Grade Glioma, Recurrent Glioblastoma Multiforme (GBM), Refractory Hodgkin Lymphoma, Refractory Multiple Myeloma, Refractory Non-Hodgkin's lymphoma

Associated Therapies: -

Clinical Trials

Lenalidomide Therapy After Chemotherapy & Stem Cell Transplant in Treating Chemotherapy Resistan Non-Hodgkin Lymphoma

Phase 1

Completed

Conditions: Recurrent Non-Hodgkin Lymphoma
Anaplastic Large Cell Lymphoma, ALK-Negative
Recurrent Anaplastic Large Cell Lymphoma
Recurrent Transformed Non-Hodgkin Lymphoma
Recurrent Mantle Cell Lymphoma
Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma

Interventions: Procedure: Autologous Hematopoietic Stem Cell Transplantation
Drug: Carmustine
Drug: Cytarabine
Drug: Etoposide
Drug: Lenalidomide
Drug: Melphalan
Biological: Rituximab

First Posted Date: 2009-12-18

Last Posted Date: 2023-10-10

Lead Sponsor: University of Nebraska

Target Recruit Count: 74

Registration Number: NCT01035463

Locations: 🇺🇸
University of Kansas Hospital-Westwood Cancer Center, Westwood, Kansas, United States
🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸
Seidman Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma

Phase 2

Completed

Conditions: Central Nervous System Lymphoma

Interventions: Drug: Methotrexate
Radiation: radiotherapy
Drug: Ara-C
Drug: Rituximab
Drug: BCNU
Other: APBSCT
Drug: Thiotepa

First Posted Date: 2009-11-11

Last Posted Date: 2017-08-23

Lead Sponsor: International Extranodal Lymphoma Study Group (IELSG)

Target Recruit Count: 126

Registration Number: NCT01011920

Locations: 🇨🇭
IOSI - Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
🇮🇹
A.O. SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
🇩🇪
Uniklinik Freiburg, Freiburg, Germany

and more 20 locations

Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia

Phase 2

Completed

Conditions: Recurrent Childhood Hodgkin Lymphoma
Refractory Small Lymphocytic Lymphoma
Waldenstrom Macroglobulinemia
Plasma Cell Leukemia
Progression of Multiple Myeloma or Plasma Cell Leukemia
Recurrent Adult Non-Hodgkin Lymphoma
Recurrent Childhood Non-Hodgkin Lymphoma
Recurrent Small Lymphocytic Lymphoma
Refractory Childhood Hodgkin Lymphoma
t(14;16)

Interventions: Procedure: Allogeneic Bone Marrow Transplantation
Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Procedure: Autologous Hematopoietic Stem Cell Transplantation
Procedure: Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation
Drug: Carmustine
Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Etoposide
Drug: Fludarabine Phosphate
Other: Laboratory Biomarker Analysis
Drug: Melphalan
Drug: Mycophenolate Mofetil
Procedure: Peripheral Blood Stem Cell Transplantation
Drug: Tacrolimus
Radiation: Total-Body Irradiation

First Posted Date: 2009-11-05

Last Posted Date: 2019-06-11

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 16

Registration Number: NCT01008462

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸
Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States

Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma

Phase 2

Completed

Conditions: Non-Hodgkin Lymphoma
Adult Diffuse Large B-Cell Lymphoma
B-Cell Non-Hodgkin Lymphoma
Follicular Lymphoma
Mantle Cell Lymphoma
T-Cell Non-Hodgkin Lymphoma

Interventions: Procedure: Autologous Hematopoietic Stem Cell Transplantation
Drug: Bortezomib
Drug: Carmustine
Drug: Cytarabine
Drug: Etoposide
Drug: Melphalan
Drug: Rituximab
Drug: Vorinostat

First Posted Date: 2009-10-09

Last Posted Date: 2020-03-18

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 27

Registration Number: NCT00992446

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies

Phase 1

Completed

Conditions: B-cell Lymphoma
Lymphoma

Interventions: Procedure: Leukapheresis
Procedure: Stem Cell Transplant
Procedure: CD19-specific T Cell Infusion
Drug: Carmustine
Drug: IL-2
Drug: Etoposide
Drug: Melphalan
Drug: Cytarabine

First Posted Date: 2009-08-31

Last Posted Date: 2023-12-19

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 34

Registration Number: NCT00968760

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

O6-Benzylguanine and Topical Carmustine in Treating Patients With Early-Stage IA-IIA Cutaneous T-Cell Lymphoma

Phase 1

Completed

Conditions: Stage II Mycosis Fungoides and Sezary Syndrome AJCC v7
Stage I Mycosis Fungoides and Sezary Syndrome AJCC v7
Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma

Interventions: Drug: Carmustine
Other: Laboratory Biomarker Analysis
Drug: O6-Benzylguanine

First Posted Date: 2009-08-18

Last Posted Date: 2018-05-22

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 17

Registration Number: NCT00961220

Locations: 🇺🇸
Henry Ford Hospital, Detroit, Michigan, United States
🇺🇸
Case Comprehensive Cancer Center, Cleveland, Ohio, United States
🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

and more 1 locations

Three Different Therapy Regimens in Treating Patients With Previously Untreated Hodgkin Lymphoma

First Posted Date: 2009-06-15

Last Posted Date: 2016-09-16

Lead Sponsor: French Innovative Leukemia Organisation

Target Recruit Count: 442

Registration Number: NCT00920153

Locations: 🇫🇷
FILO French Innovative Leukemia Organization, Tours Cedex, France

Carmustine, Etoposide, Cytarabine, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Phase 2

Conditions: Lymphoma

First Posted Date: 2009-05-25

Last Posted Date: 2013-08-02

Lead Sponsor: Cancer Research UK

Target Recruit Count: 47

Registration Number: NCT00908180

Bevacizumab and Carmustine in Treating Patients With Relapsed or Progressive High-Grade Glioma

Phase 2

Completed

Conditions: Glioma

Interventions: Drug: bevacizumab
Drug: carmustine

First Posted Date: 2008-11-21

Last Posted Date: 2020-05-12

Lead Sponsor: University of California, Davis

Target Recruit Count: 7

Registration Number: NCT00795665

Locations: 🇺🇸
University of California Davis Cancer Center, Sacramento, California, United States

Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma

Phase 3

Terminated

Conditions: Anaplastic Astrocytoma
Glioblastoma

Interventions: Drug: temozolomide
Drug: trabedersen
Drug: carmustine
Device: Drug delivery system for administration of AP 12009
Procedure: Placement of Drug Delivery System
Drug: lomustine

First Posted Date: 2008-09-29

Last Posted Date: 2014-11-14

Lead Sponsor: Isarna Therapeutics GmbH

Target Recruit Count: 27

Registration Number: NCT00761280

Locations: 🇦🇷
FLENI, Ciudad Autónoma de Buenos Aires, Argentina
🇺🇸
NJ Neuroscience Institute; JFK Medical Center, Edison, New Jersey, United States
🇺🇸
University of Rochester Medical Center, Rochester, New York, United States

and more 64 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy